

3 12/12- 3600 #9

**HUMAN GENOME SCIENCES
LEGAL DEPARTMENT**

9410 Key West Avenue
Rockville, MD 20850

Phone: 301-309-8504

Fax: 301-309-8439

FAX COVER SHEET

Date: December 10, 2002

Total pages: 8

To: Group 1600 Customer Service Center
U.S. Patent and Trademark Office

Fax 703-746-9195

From: Brenda Allen (301) 340-3459
for Lin J. Hymel (Reg. No. 45,414)

Re: Application Serial No. 10/021,002 (Atty. Docket No. PF150D2)

TRANSMITTING:

1. Request for Corrected Filing Receipt (2 pages);
2. Copy of Filing Receipt with correction noted thereon (2 pages); and
3. Copy of page 1 of Specification and page 3 of Application Data Sheet filed with instant application, along with a copy of the PTO date-stamped postcard evidencing receipt of same (3 pages).

If you experience any difficulty receiving this transmission,
please contact Brenda Allen at 301-340-3459

The information contained in this facsimile message is information protected by attorney-client and/or the attorney/work product privilege. It is intended only for the use of the individual named above and the privileges are not waived by virtue of this having been sent by facsimile. If the person actually receiving this facsimile or any other reader of the facsimile is not the named recipient or the employee or agent responsible to deliver it to the named recipient, any use, dissemination, distribution or copying of the communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address via U.S. Postal Service.

VIA FACSIMILE TRANSMISSION TO
GROUP 1600 CUSTOMER SERVICE
(703/746-9195) DECEMBER 10, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
He et al.

Docket No.: PF150D2

Application No.: 10/021,002

Group Art Unit: 1642

Filed: December 19, 2001

Examiner: Not Yet Assigned

For: Human Prostatic Specific Reductase

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Applicants hereby request that a corrected Filing Receipt be issued and sent to the undersigned representative. Specifically, the following correction is requested:

1. Under the heading Domestic Priority as claimed by applicant, please change
"WHICH IS A CIP OF PCT/US95/08127 06/29/1995*" to read
--WHICH IS A CIP OF PCT/US95/01827 01/20/1995--.

In support of the above request, Applicants submit herewith a copy of first page of the Specification and a copy of page 3 of the Application Data Sheet filed in the instant application, along with a copy of the PTO date-stamped postcard evidencing receipt of these items with the initial application papers. A copy of the Filing Receipt with the correction noted thereon is also attached.

Applicants additionally request that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicants believe no fee is due with this request because the error was generated by the Patent and Trademark Office. However, if a fee is due, please charge our Deposit Account No. 08-3425.

Dated: 10 December 2002

Respectfully submitted,

By Lin J. Hymel
Lin J. Hymel

Registration No.: 45,414
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 251-6015
Attorneys for Applicant

KKH/LJH/FR/ba

HUMAN PROSTATIC SPECIFIC REDUCTASE

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of U.S. Application No. 09/123,386, filed July 27, 1998, allowed, which is a divisional of U.S. Application No. 08/464,400 filed June 5, 1995, now U.S. Patent No. 5,786,204 which is a continuation-in-part of International Application No. PCT/US95/01827 filed January 20, 1995, which was published by the International Bureau as International Publication No. WO96/22360 on July 25, 1996 in English, each of which is hereby incorporated by reference in its entirety.

INTRODUCTION

[0002] This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, and the use of such polynucleotides and polypeptides as part of a diagnostic assay for detecting the presence of prostate cancer and prostate cancer metastases. The polynucleotides and polypeptides of the present invention are human prostatic specific reductase, and are sometimes hereinafter referred to as "PSR".

BACKGROUND OF THE INVENTION

[0003] Carcinoma of the prostate has long been regarded as an unpredictable disorder which makes sound therapeutic decisions in evaluating the results of different types of treatment very difficult. Prostate cancer is unique among the potentially lethal human malignancies in that there is a wide discrepancy between the high prevalence of histologic changes recognizable as cancer and the much lower prevalence of clinical disease.

[0004] The concept that adenocarcinoma of the prostate exists in a latent and a clinical form is supported by epidemiologic, pathologic and clinical evidence. Although these divergent manifestations of prostate cancer have come in architectural and cytologic features, they can be distinguished from each other to some degree by differences in certain pathologic features, such as the volume, grade, and invasiveness of the lesion.

[0005] Prostate cancer has become the most common cancer among American men, and only lung cancer is responsible for more cancer deaths (Boring, C.C., Cancer Statistics, 41:19-36 (1991)). The age specific mortality rate has slowly increased over the past 50 years and in black American men is nearly double the rate found in white men

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Craig
Middle Name:: A.
Family Name:: Rosen
City of Residence:: Laytonsville
State or Province of Residence:: MD
Country of Residence:: US
Street of mailing address:: 22400 Rolling Hill Lane
City of mailing address:: Laytonsville
State or Province of mailing address:: MD
Country of mailing address:: US
Postal or Zip Code of mailing address:: 20882

Correspondence Information


Correspondence Customer Number:: 22195

Representative Information


Representative Customer Number:: 22195

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	Division of	09/123,386	07/27/98
09/123,386	Division of	08/464,400	06/05/95
08/464,400	Continuation-in-part of	PCT/US95/01827	01/20/95



RETURN RECEIPT CARD
(MPEP § 503)

OIPE:	Please Date Stamp In The Box Below And Return To Addressee
	

Application of: He et al.

Attorney Docket No.: PF150D2

Application Serial No.: Unassigned

Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: Human Prostatic Specific Reductase

**The following documents were filed by Human Genome Sciences, Inc.
via hand delivery on December 19, 2001:**

1. Return Receipt Card;
2. Serial Number Postcard;
3. Fee Transmittal with appropriate fee(s) (in duplicate);
4. Utility Application Transmittal;
5. Application Data Sheet (4 pgs.);
6. Specification: 31 pgs. Description; 4 pgs. [40] Claims; 1 pg. Abstract;
7. Sequence Listing in written (on paper) (4 pgs.) and computer readable forms;
8. Statement Under 37 C.F.R. 1.821(f);
9. Figures 1A-1B and 2A-2D (6 sheets);
10. Information Disclosure Statement with Form PTO/SB/08 and copy of reference AR;
11. Copy of executed Declaration from prior Application No. 08/464,400; and
12. Copy of Assignment papers from prior Application No. 08/464,400.

JKE/CCB/ba



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/021,002	12/19/2001	1642	1352	PF150D2	6	40	6

22195
HUMAN GENOME SCIENCES INC
9410 KEY WEST AVENUE
ROCKVILLE, MD 20850

CONFIRMATION NO. 9797

FILING RECEIPT



0000000007756196

APR 13 2002

KKH CB

Date Mailed: 04/01/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Wei-Wu He, Columbia, MD; ✓
Paul S. Meissner, Barnesville, MD; ✓
Peter L. Hudson, Germantown, MD; ✓
Craig A. Rosen, Laytonsville, MD; ✓

Assignment For Published Patent Application

Human Genome Sciences, Inc., Rockville, MD; ✓

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/123,386 07/27/1998 PAT 6,344,198 ✓

WHICH IS A DIV OF 08/464,400 06/05/1995 PAT 5,786,204 ✓

WHICH IS A CIP OF PCT/US95/08427 06/29/1995 ✓ PCT/US95/01827 01/20/1995

(*) Data inconsistent with PTO records

Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title

Human prostatic specific reductase

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).